|
1.
|
Uchiyama T: Human T cell leukemia virus
type I (HTLV-I) and human diseases. Annu Rev Immunol. 15:15–37.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Grant C, Barmak K, Alefantis T, Yao J,
Jacobson S and Wigdahl B: Human T cell leukemia virus type I and
neurologic disease: events in bone marrow, peripheral blood, and
central nervous system during normal immune surveillance and
neuroinflammation. J Cell Physiol. 190:133–159. 2002. View Article : Google Scholar
|
|
3.
|
Okochi K, Sato H and Hinuma Y: A
retrospective study on transmission of adult T cell leukemia virus
by blood transfusion: seroconversion in recipients. Vox Sang.
46:245–253. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Okayama A, Stuver S, Matsuoka M, Ishizaki
J, Tanaka G, Kubuki Y, Mueller N, Hsieh CC, Tachibana N and
Tsubouchi H: Role of HTLV-1 proviral DNA load and clonality in the
development of adult T-cell leukemia/lymphoma in asymptomatic
carriers. Int J Cancer. 110:621–625. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Matsuzaki T, Nakagawa M, Nagai M, Usuku K,
Higuchi I, Arimura K, Kubota H, Izumo S, Akiba S and Osame M:
HTLV-I proviral load correlates with progression of motor
disability in HAM/TSP: analysis of 239 HAM/TSP patients including
64 patients followed up for 10 years. J Neurovirol. 7:228–234.
2001.PubMed/NCBI
|
|
6.
|
Taylor GP, Tosswill JH, Matutes E, Daenke
S, Hall S, Bain BJ, Davis R, Thomas D, Rossor M, Bangham CR and
Weber JN: Prospective study of HTLVI infection in an initially
asymptomatic cohort. J Acquir Immune Defic Syndr. 22:92–100. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hisada M, Okayama A, Shioiri S, Spiegelman
DL, Stuver SO and Mueller NE: Risk factors for adult T-cell
leukemia among carriers of human T-lymphotropic virus type I.
Blood. 92:3557–3561. 1998.PubMed/NCBI
|
|
8.
|
Okayama A and Stuver SO: Long-term
follow-up of HTLV-1 carriers. Gann Monogr Cancer Res. 50:127–139.
2003.
|
|
9.
|
Nitta T, Tanaka M, Sun B, Hanai S and Miwa
M: The genetic background as a determinant of human T-cell leukemia
virus type 1 proviral load. Biochem Biophys Res Commun.
309:161–165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Nitta T, Tanaka M, Sun B, Sugihara E,
Kimura M, Kamada Y, Takahashi H, Hanai S, Jiang SW, Fujisawa J and
Miwa M: Reduction of human T-cell leukemia virus type-1 infection
in mice lacking nuclear factor-kappaB-inducing kinase. Cancer Sci.
99:872–878. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tanaka M, Sun B, Fang J, Nitta T, Yoshida
T, Kohtoh S, Kikukawa H, Hanai S, Uchida K and Miwa M: Human T-cell
leukemia virus type 1 (HTLV-1) infection of mice: proliferation of
cell clones with integrated HTLV-1 provirus in lymphoid organs. J
Virol. 75:4420–4423. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Fang J, Kushida S, Feng R, Tanaka M,
Kawamura T, Abe H, Maeda N, Onobori M, Hori M, Uchida K and Miwa M:
Transmission of human T-cell leukemia virus type 1 to mice. J
Virol. 72:3952–3957. 1998.PubMed/NCBI
|
|
13.
|
Miyoshi I, Kubonishi I, Yoshimoto S, Akagi
T, Ohtsuki Y, Shiraishi Y, Nagata K and Hinuma Y: Type C virus
particles in a cord T-cell line derived by co-cultivating normal
human cord leukocytes and human leukaemic T cells. Nature.
294:770–771. 1981. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kato H, Koya Y, Ohashi T, Hanabuchi S,
Takemura F, Fujii M, Tsujimoto H, Hasegawa A and Kannagi M: Oral
administration of human T-cell leukemia virus type 1 induces immune
unresponsiveness with persistent infection in adult rats. J Virol.
72:7289–7293. 1998.PubMed/NCBI
|
|
15.
|
Persaud D, Munoz JL, Tarsis SL, Parks ES
and Parks WP: Time course and cytokine dependence of human T-cell
lymphotropic virus type 1 T-lymphocyte transformation as revealed
by a microtiter infectivity assay. J Virol. 69:6297–6303. 1995.
|
|
16.
|
Satoh M, Toma H, Sugahara K, Etoh K,
Shiroma Y, Kiyuna S, Takara M, Matsuoka M, Yamaguchi K, Nakada K,
Fujita K, Kojima S, Hori E, Tanaka Y, Kamihira S, Sato Y and
Watanabe T: Involvement of IL-2/IL-2R system activation by parasite
antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected
T-cells in human carriers of both HTLV-1 and S. stercoralis.
Oncogene. 21:2466–2475. 2002.PubMed/NCBI
|
|
17.
|
Popovic M, Lange-Wantzin G, Sarin PS, Mann
D and Gallo RC: Transformation of human umbilical cord blood T
cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci
USA. 80:5402–5406. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Imada K, Takaori-Kondo A, Akagi T,
Shimotohno K, Sugamura K, Hattori T, Yamabe H, Okuma M and Uchiyama
T: Tumorigenicity of human T-cell leukemia virus type I-infected
cell lines in severe combined immunodeficient mice and
characterization of the cells proliferating in vivo. Blood.
86:2350–2357. 1995.PubMed/NCBI
|
|
19.
|
Ishihara S, Tachibana N, Okayama A, Murai
K, Tsuda K and Mueller N: Successful graft of HTLV-I-transformed
human T-cells (MT-2) in severe combined immunodeficiency mice
treated with anti-asialo GM-1 antibody. Jpn J Cancer Res.
83:320–323. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lairmore MD, Silverman L and Ratner L:
Animal models for human T-lymphotropic virus type 1 (HTLV-1)
infection and transformation. Oncogene. 24:6005–6015. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Dewan MZ, Terashima K, Taruishi M,
Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M,
Kubuki Y, Okayama A, Fujii M and Yamamoto N: Rapid tumor formation
of human T-cell leukemia virus type 1-infected cell lines in novel
NOD-SCID/gammac(null) mice: suppression by an inhibitor against
NF-kappaB. J Virol. 77:5286–5294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ohsugi T, Horie R, Kumasaka T, Ishida A,
Ishida T, Yamaguchi K, Watanabe T, Umezawa K and Urano T: In vivo
antitumor activity of the NF-kappaB inhibitor
dehydroxymethyl-epoxyquinomicin in a mouse model of adult T-cell
leukemia. Carcinogenesis. 26:1382–1388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Simpson RM, Zhao TM, Schmidt HB, Said W
and Kindt TJ: Source and route of exposure influence infectivity of
a molecular clone of human T cell leukemia virus type I. AIDS Res
Hum Retroviruses. 14:711–715. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hasegawa A, Ohashi T, Hanabuchi S, Kato H,
Takemura F, Masuda T and Kannagi M: Expansion of human T-cell
leukemia virus type 1 (HTLV-1) reservoir in orally infected rats:
inverse correlation with HTLV-1-specific cellular immune response.
J Virol. 77:2956–2963. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Jude BA, Pobezinskaya Y, Bishop J, Parke
S, Medzhitov RM, Chervonsky AV and Golovkina TV: Subversion of the
innate immune system by a retrovirus. Nat Immunol. 4:573–578. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Panoutsakopoulou V, Little CS, Sieck TG,
Blankenhorn EP and Blank KJ: Differences in the immune response
during the acute phase of E-55+ murine leukemia virus
infection in progressor BALB and long term nonprogressor C57BL
mice. J Immunol. 161:17–26. 1998.PubMed/NCBI
|
|
27.
|
Osame M, Janssen R, Kubota H, Nishitani H,
Igata A, Nagataki S, Mori M, Goto I, Shimabukuro H and Khabbaz R:
Nationwide survey of HTLV-1-associated myelopathy in Japan:
association with blood transfusion. Ann Neurol. 28:50–56. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Jones KS, Akel S, Petrow-Sadowski C, Huang
Y, Bertolette DC and Ruscetti FW: Induction of human T cell
leukemia virus type I receptors on quiescent naive T lymphocytes by
TGF-beta. J Immunol. 174:4262–4270. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Moriuchi M and Moriuchi H: A milk protein
lactoferrin enhances human T cell leukemia virus type I and
suppresses HIV-1 infection. J Immunol. 166:4231–4236. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Moriuchi M and Moriuchi H: Transforming
growth factor-beta enhances human T-cell leukemia virus type I
infection. J Med Virol. 67:427–430. 2002. View Article : Google Scholar : PubMed/NCBI
|
